The availability of such tools and biomarkers will allow to screen cancer patients and select those showing SMO and GLI activation, increasing the subset of cancer patients who will likely respond to HH-GLI pathway inhibition and to monitor the efficacy of therapy. This evidence concerns the gene GLI1 and cancer.